Skip to content
Company Analysis

Xeris Biopharma Holdings, Inc. XERS

A comprehensive view of key metrics, scores, and financial health for Xeris Biopharma Holdings, Inc.

Overview of Xeris Biopharma Holdings, Inc.

XERS NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Small Cap
Xeris Biopharma Holdings, Inc. (XERS), is a Small Cap company, in the Biotechnology industry, last closed at $10.17, about 67.5% overvalued vs fair value, +31.9% 1Y return, placing in the top 10% of its sector.
Metrics P/E 2447.7× Rev Growth 43.7% ROE -7.0% Gross Margin 85.4%
USD 10.17
-5.04%
(Delayed)
• Vol 90d: 52.9%
52-Week Range
Market Cap
$1.85B
Enterprise Value
$1.99B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Fair
Completeness: 88%
Confidence: 93%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.xerispharma.com
HQ Chicago, IL
Employees 435
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$3
$3
$4
Current: $10.17 -68% vs base

Engine Room Money Flow™

Small Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$111.0M
55%%
Total Revenue
$291.8M
43.7%%
Net Income
$554.0K
101%%
Operating Expense
$224.4M
12.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
13.9%
Poor

Low R&D intensity for a biotech - potential concern

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Xeris Biopharma Holdings, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.83), demonstrating pricing resilience across cycles.
  • Cost Leadership Position Operating margin at 89.1th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.24), raising questions about short-term obligations.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.16), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
73
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 60% Coverage
Trade-Off Triangle Visualization A ternary plot showing XERS's balance between Growth (42.1%), Profitability (29.8%), and Safety (28.0%). Growth 42% Safety 28% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

47th percentile vs peers
47
Key Signals
TSR -17.7% 47p
Strengths

No notable strengths identified for this axis.

Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

31th percentile vs peers
31
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Xeris Biopharma Holdings, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$3.31
- - -
-67.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000